应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
BK1161 生物科技
未开盘 08-27 16:00:00
5,535.119
+39.109
+0.71%
最高
5,553.910
最低
5,435.696
成交量
2.58亿
今开
5,498.813
昨收
5,496.010
日振幅
2.15%
总市值
0.00
流通市值
0.00
总股本
0.00
成交额
81.50亿
换手率
--
流通股本
0.00
市净率
5.864255
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
股市必读：百奥赛图新发布《百奥赛图（北京）医药科技股份有限公司2026年第三次临时股东会会议资料》
证券之星 · 45分钟前
股市必读：百奥赛图新发布《百奥赛图（北京）医药科技股份有限公司2026年第三次临时股东会会议资料》
博安生物(06955.HK)中期亏损8300万元 同比由盈转亏
中金财经 · 08-27 22:57
博安生物(06955.HK)中期亏损8300万元 同比由盈转亏
信达生物(01801.HK)因购股权获行使而合共发行18.2万股
智通财经 · 08-27 22:54
信达生物(01801.HK)因购股权获行使而合共发行18.2万股
诺禾致源：8月25日召开业绩说明会，国联民生医药、东吴证券参与
证券之星 · 08-27 22:52
诺禾致源：8月25日召开业绩说明会，国联民生医药、东吴证券参与
博安生物(06955)：订立融资租赁协议
智通财经 · 08-27 22:47
博安生物(06955)：订立融资租赁协议
和铂医药－Ｂ(02142.HK)：陈侑晨及刘毅获委任为执行董事
中金财经 · 08-27 22:37
和铂医药－Ｂ(02142.HK)：陈侑晨及刘毅获委任为执行董事
山东博安生物：兴业金融租赁公司将购回租赁资产
美股速递 · 08-27 22:35
山东博安生物：兴业金融租赁公司将购回租赁资产
山东博安生物：租赁资产系指兴业金融租赁所持有的相关机械设备
美股速递 · 08-27 22:35
山东博安生物：租赁资产系指兴业金融租赁所持有的相关机械设备
康方生物(09926.HK)中期亏损为4.47亿元 同比收窄约24.0%
中金财经 · 08-27 22:27
康方生物(09926.HK)中期亏损为4.47亿元 同比收窄约24.0%
维升药业-B(02561.HK)核心产品获批开启商业化 上半年实现收入3454.2万元
智通财经 · 08-27 22:22
维升药业-B(02561.HK)核心产品获批开启商业化 上半年实现收入3454.2万元
维升药业-B(02561.HK)：YAO Zhengbin (Bing)辞任独立非执行董事
智通财经 · 08-27 22:16
维升药业-B(02561.HK)：YAO Zhengbin (Bing)辞任独立非执行董事
和铂医药-B(02142.HK)：陈侑晨获委任为执行董事
智通财经 · 08-27 22:10
和铂医药-B(02142.HK)：陈侑晨获委任为执行董事
康方生物(09926.HK)发布中期业绩 收入同比增加27.92%至18.06亿元
智通财经 · 08-27 22:09
康方生物(09926.HK)发布中期业绩 收入同比增加27.92%至18.06亿元
康宁杰瑞制药-B(09966.HK)发布中期业绩，股东应占亏损4046.1万元 同比盈转亏
智通财经 · 08-27 22:09
康宁杰瑞制药-B(09966.HK)发布中期业绩，股东应占亏损4046.1万元 同比盈转亏
和铂医药-B(02142)发布中期业绩 期内溢利6485.1万美元 同比减少11.16%
智通财经 · 08-27 22:08
和铂医药-B(02142)发布中期业绩 期内溢利6485.1万美元 同比减少11.16%
和铂医药-B发布2026年中期业绩：三大协同增长引擎加速平台战略落地
美股速递 · 08-27 22:06
和铂医药-B发布2026年中期业绩：三大协同增长引擎加速平台战略落地
和铂医药公布2026年中期业绩：三大增长引擎持续发力，平台型战略加速兑现
美通社 · 08-27 22:04
和铂医药公布2026年中期业绩：三大增长引擎持续发力，平台型战略加速兑现
宜明昂科-B(01541)：IMM2510联合IMM27M一线治疗晚期HCC的II期临床试验完成首例患者给药
智通财经 · 08-27 21:21
宜明昂科-B(01541)：IMM2510联合IMM27M一线治疗晚期HCC的II期临床试验完成首例患者给药
营收增长超40% 海外收入过亿 康希诺生物国际化从“布局”走向“兑现”
格隆汇 · 08-27 21:13
营收增长超40% 海外收入过亿 康希诺生物国际化从“布局”走向“兑现”
宏辉果蔬半年报：利润总额同比增长超250%，医药业务并表带来业绩新变化
新浪证券 · 08-27 20:15
宏辉果蔬半年报：利润总额同比增长超250%，医药业务并表带来业绩新变化
加载更多
公司概况
公司名称：
BK1161
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":5535.119,"timestamp":1787818109125,"preClose":5496.01,"halted":0,"volume":258385883,"delay":0,"changeRate":0.007116,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":39.109375,"latestTime":"08-27 16:00:00","open":5498.8125,"high":5553.9097,"low":5435.6963,"amount":8149937772.5,"amplitude":0.021509,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787880600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787794200000,1787803200000],[1787806800000,1787817600000]],"pbRate":5.864255,"peRate":248.260075,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161","defaultTab":"news","newsList":[{"id":"2662350850","title":"股市必读：百奥赛图新发布《百奥赛图（北京）医药科技股份有限公司2026年第三次临时股东会会议资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662350850","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662350850?lang=zh_cn&edition=full","pubTime":"2026-08-28 05:30","pubTimestamp":1787866234,"startTime":"0","endTime":"0","summary":"百奥赛图（北京）医药科技股份有限公司2026年度“提质增效重回报”专项行动方案的半年度评估报告2026年上半年临床前产品及服务业务收入72,349.19万元，同比增长57.94%，毛利率约75.22%；抗体发现业务收入21,785.97万元，同比增长33.77%，毛利率达92.82%；研发费用26,733.78万元，同比增长27.85%；累计签署药物合作开发协议超455项，新增超105项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800009783.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0216","159938","688796","09939","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662089551","title":"博安生物(06955.HK)中期亏损8300万元 同比由盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2662089551","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662089551?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:57","pubTimestamp":1787842621,"startTime":"0","endTime":"0","summary":"格隆汇8月27日丨博安生物发布截至2026年6月30日止六个月之中期业绩。集团的收入约为人民币2.33亿元，同比下降40.8%。期内亏损为人民币8300万元，而截至2025年6月30日止六个月为溢利人民币2050万元，每股基本亏损0.13元。集团的研究及开发开支约为人民币9200万元，较截至2025年6月30日止六个月增加约人民币3340万元。 商业化方面，于2026年1月，集团的60mg地舒单抗注射液(博优倍)已获玻利维亚国家药品和卫生技术局批准上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260827/32350747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662063086","title":"信达生物(01801.HK)因购股权获行使而合共发行18.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662063086","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662063086?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:54","pubTimestamp":1787842459,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1188198961.HKD","01801","LU2488822045.USD","KURE","LU2328871848.SGD","LU2097828631.EUR","LU2097828557.USD","LU2242644610.SGD","LU0326950275.SGD","LU0463099449.HKD","BK1583","BK1161","BK1589","HK0000165453.HKD","LU2097828474.EUR","LU0502904849.HKD","LU0244354667.USD","LU0455707207.USD","LU1969619763.USD","LU2097828714.EUR","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662508981","title":"诺禾致源：8月25日召开业绩说明会，国联民生医药、东吴证券参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2662508981","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662508981?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:52","pubTimestamp":1787842337,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年8月27日诺禾致源发布公告称公司于2026年8月25日召开业绩说明会，国联民生医药杨芳、东吴证券刘若彤参与。公司2026年上半年实现归属于上市公司股东的净利润6,312.26万元，同比下降19.82%；毛利率41.86%，同比增加1.06个百分点；研发支出9,123.87万元，同比增长45.73%，占营业收入8.19%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700056904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688315","BK1564","BK0188","601456","BK0221","BK1515","BK0012","09939","601555","BK0009","BK0276","01456","BK0216","BK1161","BK1147","BK0028","BK0183","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662086798","title":"博安生物(06955)：订立融资租赁协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2662086798","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662086798?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:47","pubTimestamp":1787842037,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物(06955)发布公告，于2026年8月27日，公司(承租人)与兴业金租订立融资租赁协议，据此，兴业金租将自公司购买租赁资产并将于租赁期内向公司出租该等租赁资产，但可根据融资租赁协议的条款及条件提早终止。租赁资产为兴业金租所租赁的若干机械及设备。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662086194","title":"和铂医药－Ｂ(02142.HK)：陈侑晨及刘毅获委任为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2662086194","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662086194?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:37","pubTimestamp":1787841424,"startTime":"0","endTime":"0","summary":"格隆汇8月27日丨和铂医药－Ｂ(02142.HK)发布公告，戎一平因个人原因已辞任执行董事，自2026年8月27日(“生效日期”)起生效。\r\n\r\n 经考虑董事会提名委员会的推荐建议后，自生效日期起，陈侑晨及刘毅已获委任为执行董事。此外，陈侑晨已获委任为授权代表，自生效日期起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260827/32350739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","BK1161","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153864545","title":"山东博安生物：兴业金融租赁公司将购回租赁资产","url":"https://stock-news.laohu8.com/highlight/detail?id=1153864545","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153864545?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:35","pubTimestamp":1787841309,"startTime":"0","endTime":"0","summary":"山东博安生物技术股份有限公司（06955.HK）宣布，兴业金融租赁有限责任公司将从公司手中购回租赁资产。此举标志着双方在租赁业务上的又一重要合作进展。据悉，该交易涉及具体的资产购回安排，进一步优化公司的资产结构。博安生物作为生物制药领域的创新企业，此次资产处置或为其带来资金流动性支持，助力研发与业务拓展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141997819","title":"山东博安生物：租赁资产系指兴业金融租赁所持有的相关机械设备","url":"https://stock-news.laohu8.com/highlight/detail?id=1141997819","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141997819?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:35","pubTimestamp":1787841308,"startTime":"0","endTime":"0","summary":"山东博安生物公告，其租赁资产所指，正是兴业金融租赁所出租的部分机械设备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662808658","title":"康方生物(09926.HK)中期亏损为4.47亿元 同比收窄约24.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662808658","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662808658?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:27","pubTimestamp":1787840823,"startTime":"0","endTime":"0","summary":"格隆汇8月27日丨康方生物(09926.HK)发布截至2026年6月30日止六个月之中期业绩。2026年上半年，集团总收入为人民币18.06亿元，同比增长27.92%。集团的亏损为人民币4.47亿元，同比收窄约24.0%。每股基本亏损0.46元。\r\n\r\n 集团收入的构成包括商业销售收入及商业授权收入。2026年上半年商业销售收入为人民币1,803.2百万元，2025年上半年为人民币1,401.6百万元，同比增长28.65%。2026年上半年商业授权收入为人民币2.5百万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260827/32350719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IE00B543WZ88.USD","LU2476274720.SGD","IE00BPRC5H50.USD","LU0417516902.SGD","LU0348735423.USD","LU2476274308.USD","LU0348784397.USD","LU2778985437.USD","BK1574","LU1961090484.USD","LU0348825331.USD","LU0348783233.USD","LU0348827113.USD","LU0561508036.HKD","LU0417516738.SGD","LU2399975544.HKD","LU2488822045.USD","LU0348766576.USD","LU0540923850.HKD","LU1794554557.SGD","LU0417516571.SGD","LU1720050803.USD","KURE","09926","LU0348767384.USD","IE00B5MMRT66.SGD","LU0634319403.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085038","title":"维升药业-B(02561.HK)核心产品获批开启商业化 上半年实现收入3454.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085038","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662085038?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:22","pubTimestamp":1787840575,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085145","title":"维升药业-B(02561.HK)：YAO Zhengbin (Bing)辞任独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085145","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662085145?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:16","pubTimestamp":1787840175,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085539","title":"和铂医药-B(02142.HK)：陈侑晨获委任为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085539","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662085539?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:10","pubTimestamp":1787839818,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","02142","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662855620","title":"康方生物(09926.HK)发布中期业绩 收入同比增加27.92%至18.06亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662855620","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662855620?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:09","pubTimestamp":1787839794,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0348766576.USD","LU2399975544.HKD","LU0348783233.USD","LU1720050803.USD","LU0540923850.HKD","LU0348825331.USD","LU0417516738.SGD","LU0348767384.USD","09926","LU0417516571.SGD","BK1161","IE00BPRC5H50.USD","KURE","LU2488822045.USD","LU0348784397.USD","LU0417516902.SGD","IE00B5MMRT66.SGD","LU0348735423.USD","LU0634319403.HKD","LU1961090484.USD","LU2476274720.SGD","LU0561508036.HKD","LU1794554557.SGD","LU2778985437.USD","BK1574","LU0348827113.USD","LU2476274308.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085532","title":"康宁杰瑞制药-B(09966.HK)发布中期业绩，股东应占亏损4046.1万元 同比盈转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085532","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662085532?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:09","pubTimestamp":1787839753,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085591","title":"和铂医药-B(02142)发布中期业绩 期内溢利6485.1万美元 同比减少11.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085591","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662085591?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:08","pubTimestamp":1787839699,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 发布截至2026年6月30日止6个月中期业绩，收入1.22亿美元，同比增长20.9%;期内溢利6485.1万美元，同比减少11.16%;每股基本盈利0.08美元。公告称，于报告期内，收入总额为1.22亿美元，相较于2025年上半年度1.01亿美元增长20.9%。分子授权及合作收入由9370万美元增加至1.13亿美元，主要由于与全球领先跨国制药公司的持续战略合作及创新产品对外授权及合作。同时，研究服务及技术许可费收入由760万美元增长23.8%至940万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02142","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106891965","title":"和铂医药-B发布2026年中期业绩：三大协同增长引擎加速平台战略落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1106891965","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106891965?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:06","pubTimestamp":1787839601,"startTime":"0","endTime":"0","summary":"和铂医药-B近日披露2026年中期业绩报告。这份成绩单不仅展示了公司财务状况，更清晰地勾勒出其平台化战略的执行路径——三大增长引擎正协同发力，推动业务迈向新台阶。从行业视角审视，和铂医药的这一战略实践颇具参考意义。此次中期业绩所透露的信号，不仅是财务数字的改善，更在于其验证了平台化战略在复杂市场环境中的韧性与成长性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662852180","title":"和铂医药公布2026年中期业绩：三大增长引擎持续发力，平台型战略加速兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2662852180","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662852180?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:04","pubTimestamp":1787839440,"startTime":"0","endTime":"0","summary":"和铂医药创始人、董事长兼首席执行官王劲松博士表示：\"2026年上半年，和铂医药3.0战略深入落地，三大增长引擎均取得实质性进展。三大增长引擎相互协同，使技术平台、创新管线和全球合作网络形成更加紧密的连接，加速长期价值的形成与转化。合作方Windward Bio于2025年7月启动HBM9378治疗哮喘的全球II/III期POLARIS临床研究，初步数据预计将于2026年下半年公布，III期研究计划于2026年第四季度启动。2026年7月，HBM7575治疗哮喘的中国IND申请亦获NMPA批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5033077_ZH33077_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5033077_ZH33077_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","BK1161","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662008845","title":"宜明昂科-B(01541)：IMM2510联合IMM27M一线治疗晚期HCC的II期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2662008845","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662008845?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:21","pubTimestamp":1787836891,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，IMM2510联 合 IMM27M一线治疗晚期肝细胞癌患者的II期临床试验顺利完成首例患者给药。该研究旨在评估IMM2510联合IMM27M在该患者群体中的初步疗效及安全性。自2023年首次提交IMM2510联合IMM27M的试验性新药申请以来，该联合疗法的临床开发稳步推进，并展现出卓越的潜力。令人鼓舞的早期临床结果证实，IMM2510联合IMM27M在晚期实体瘤治疗中具有显著的抗肿瘤活性及可控的安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4006","HCC","IBBJ","MDTX","BK1161","PSYK","BMED","01541","IBBQ","COAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662883710","title":"营收增长超40% 海外收入过亿 康希诺生物国际化从“布局”走向“兑现”","url":"https://stock-news.laohu8.com/highlight/detail?id=2662883710","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662883710?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:13","pubTimestamp":1787836409,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06185","BK1191","BK1161","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662707899","title":"宏辉果蔬半年报：利润总额同比增长超250%，医药业务并表带来业绩新变化","url":"https://stock-news.laohu8.com/highlight/detail?id=2662707899","media":"新浪证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662707899?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:15","pubTimestamp":1787832900,"startTime":"0","endTime":"0","summary":"今年4月27日，宏辉果蔬公告拟以7.00052亿元受让施美药业41.128%股份。对比宏辉果蔬2025年全年归母净利润1781.30万元，施美药业的净利润体量是上市公司原有盈利水平的8倍以上。传统果蔬业务方面，宏辉果蔬上半年部分经营数据出现波动。整体来看，宏辉果蔬2026年上半年业绩呈现出业务结构调整的特点。利润总额同比增长超过250%，毛利率明显提升，而施美药业仅在6月开始并表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-08-27/doc-inipuiyp9095860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603336","BK1515","BK1161","159938","BK0238","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":0.0101},{"period":"3month","weight":0.0152},{"period":"6month","weight":-0.04},{"period":"1year","weight":0.0144},{"period":"ytd","weight":-0.0025}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}